feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Brain Scans Show Weight Drug Quiets Food Cravings

Brain Scans Show Weight Drug Quiets Food Cravings

18 Nov, 2025

•

Summary

  • A GLP-1 weight-loss drug temporarily suppressed food cravings in brain scans.
  • Direct brain activity measurements show drug's impact on 'food noise'.
  • Findings suggest potential for eating disorder treatments with future drug versions.
Brain Scans Show Weight Drug Quiets Food Cravings

Researchers monitoring brain activity in a patient with a severe binge-eating disorder observed that Eli Lilly's GLP-1 weight-loss drug, tirzepatide, temporarily silenced food-craving signals in the brain's reward center. This marks the first direct measurement of brain activity in a person receiving tirzepatide, offering insights into its effect on 'food noise.'

The study, published in Nature Medicine, involved monitoring a patient undergoing deep-brain stimulation for loss-of-control eating disorders. One participant, who was prescribed tirzepatide for diabetes and obesity, showed a remarkable lack of food preoccupation and silent nucleus accumbens food-craving signals during initial monitoring.

While the drug's impact on binge-eating was temporary, suggesting it was optimized for diabetes and weight loss rather than eating disorders, the findings are promising. Researchers believe future GLP-1 drugs could be redesigned to target the brain's reward mechanisms for more lasting effects on severe food preoccupation.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Tirzepatide appeared to temporarily suppress food-craving signals in the nucleus accumbens, the brain's reward center, in one observed patient.
While current findings are preliminary, they suggest future versions of GLP-1 drugs like tirzepatide might be adapted for treating certain eating disorders.
'Food noise' refers to food preoccupation. Tirzepatide temporarily silenced these signals and reduced food preoccupation in one study participant.

Read more news on

Healthside-arrow
trending

Bears stun Green Bay Packers

trending

NFL playoff bracket updated

trending

NFL playoffs wild card weekend

trending

Grateful Dead's Bob Weir dies

trending

Hornets rout Jazz 150-95

trending

Alex Bregman joins Chicago Cubs

trending

Stafford, Robinson lead All-Pro team

trending

LaFleur contract extension talks begin

trending

Bears vs Packers showdown

You may also like

AbbVie Eyes Revolution Medicines in Cancer Deal

8 Jan • 24 reads

article image

Weight Loss Jabs: Gain Back Pounds Faster Than You Lose Them

8 Jan • 11 reads

article image

Eli Lilly Nears $1B Ventyx Buyout Deal

7 Jan • 20 reads

article image

FDA Approves Oral Wegovy: Game Changer for Dieters?

23 Dec, 2025 • 152 reads

article image

AbbVie, Lilly: Top Pharma Buys for New Year

14 Dec, 2025 • 76 reads

article image